Sivelestat Treatment for Postoperative Organ Protection in Type A Aortic Dissection
Key facts
- Who runs it
- Shanghai Zhongshan Hospital
- Where
- China7 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 236 people, planned
- Started
- 29 Sept 2025
- Expected to end
- 30 Mar 2027
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Conventional treatment
- Sivelestat sodium
- Placebo
- Record updated
- 10 November 2026
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Age 18-75 years inclusive
- Written informed consent obtained before participation
- Confirmed acute Stanford type A aortic dissection scheduled for surgical repair
Who cannot take part
- Severe pre-operative renal dysfunction: acute or chronic kidney injury meeting criteria for renal-replacement therapy
- Immunosuppression: long-term or > 2 weeks continuous systemic corticosteroids
- Concomitant or anticipated use of immunomodulators (Xue-Bi-Jing injection, thymosin, IVIG)
- Medical or psychological condition that would interfere with study participation, assessment, or outcomes
- Life expectancy ≤ 48 hours
- Pregnant or lactation
- Severe pre-operative liver dysfunction: Child-Turcotte-Pugh score 10-15
- Confirmed COPD or asthma
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this multicenter, double-blind, randomized controlled trial is to learn if sivelestat sodium (Siv) can protect the organ function in patients suffered operation for acute type A aortic dissection. The main questions it aims to answer are:
Read full original descriptionShow less
* Can the 3-day-treatment of Siv enlarge the Day-0-to-Day-5 drop in the organ-health score (SOFA score)? * Can this treatment significantly shrink the area under the SOFA curve from first dose to Day 5? * Can this treatment significantly improve the end of patients in 28 days (clinical outcomes)? Researchers will compare drug Siv to a placebo (a look-alike substance that contains no drug) to see if drug Siv works.
Participants will:
* Take drug Siv or the placebo through vein continuously for 72 hours * Receiving regular intensive care in ICU after the operation
The 2 groups in the trial
- Sivelestat groupTreatment being tested
Drug: Sivelestat Sodium. Procedure: Conventional Treatment
Treatment: Conventional treatment and Sivelestat sodium
- Control groupPlacebo, for comparison
Drug: Placebo. Procedure: Conventional Treatment
Treatment: Conventional treatment and Placebo
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Assessment of the Efficacy of Sivelestat Sodium Treatment in Post-operative Organ Dysfunction in Patients With Acute Type A Aortic Dissection (STOP): a Multicenter, Double-blind RCT
- Criteria questions
- Built from NCT07156656, who can take part
- Record updated
- 10 November 2026